The liposomal “commercial” lipid pool has little variation, and “fancy” lipids (e.g., potentially useful for gene and DNA/RNA delivery, immunological targeting, fusogenic/cationic lipids) are mostly avoided. Shaping lipids into liposomes is becoming more of an engineering act than an art form. The first bioequivalent doxorubicin liposome has been approved.
Subject area:
Excipients
Objectives (If applicable):
n/a
Target Audience (If applicable):